Ipsen Sponsored Symposium
Tuesday 13:30-14:15, Hall 11
Neuroendocrine tumours (NETs) commonly arise at sites within the gastrointestinal tract and pancreas. They are thought of as rare ‘zebras’ of the gastroenterology and cancer world; however, NETs are more prevalent than any other gastrointestinal cancer except colorectal adenocarcinoma.1 Despite this, there is often a significant delay in diagnosis and over 40% of patients have metastases at diagnosis.2
Patients with NETs can face diagnostic delays of 5 years due to vague symptoms, with many initially misdiagnosed with a more common condition such as irritable bowel syndrome.1–3 Although patients can survive for years with metastatic disease, living with NETs is associated with both physical and emotional challenges.1,4
Many patients with NETs are referred to gastroenterologists and hepatologists, following investigation by primary care, providing these specialties with a unique opportunity to diagnose NETs earlier, helping to prevent diagnostic delays.1
Led by Consultant Gastroenterologists Professor Mark Pritchard and Dr Mohid Khan, leads of their respective European Neuroendocrine Tumour Centres of Excellence, this symposium will focus on the routes via which gastroenterologists and hepatologists may encounter patients with NETs. Through engaging case studies, panel discussions and sharing of best practice, we will explore how to better identify the zebras among our patients.
Disclaimer and References
Disclaimer: This is a promotional educational meeting organised and fully funded by Ipsen.
1. Khan MS, Pritchard DM. Neuroendocrine tumours: what gastroenterologists need to know.Frontline Gastroenterol. 2022;13:50–6.
2. Kolarova T et al. Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor Patients (SCAN): The Diagnostic Process of GEP NETs in Asia, Europe, North America and Oceania. Presented at IASCO 2021.
3. CSSC Service Development Prize Submission 2021 – Dr Mohid Khan. 2021 (UK – Wales) Available from: https://www.bsg.org.uk/service-success-stories/cssc-service-development-prize-submission-2021-dr-mohid-khan/ [Last accessed: April 2022].
4. Khan MS, et al. Patient survey of the physical, emotional, and informational challenges for patients living with neuroendocrine tumors. Oncology and Therapy. 2020;8:67–80.
April 2022 | SOM-GB-001592
Dr Mohid Khan, Consultant Gastroenterologist, Cardiff and Vale University Health Board, Clinical Lead for the South Wales ENETS Centre of Excellence
Professor Mark Pritchard, Professor of Gastroenterology and Honorary Consultant Gastroenterologist, University of Liverpool, Clinical Lead for Liverpool ENETs Centre of Excellence and current Chair of the UK and Ireland NET Society (UKINETS)
Talk Titles and Timings:
|Welcome and introduction – neuroendocrine tumours (NETs) in numbers||10 minutes||Dr Mohid Khan|
|Distinguishing a zebra from a horse – diagnosing gastroenteropancreatic (GEP)-NETs||20 minutes||Professor Mark Pritchard and Dr Mohid Khan|
|Panel discussion and Q&A||10 minutes||Professor Mark Pritchard and Dr Mohid Khan|